Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue

Launched by NATIONAL CANCER INSTITUTE (NCI) · Oct 31, 2015

Keywords

ClinConnect Summary

This clinical trial is focused on studying prostate cancer, which is the most common type of cancer among men in the U.S. The researchers aim to collect samples from men with prostate cancer, including blood, tissue, and other fluids, to better understand how changes in cells and genes can lead to the development and progression of this disease. The findings from this study may help in creating new treatments for prostate cancer.

Men aged 18 and older who have prostate cancer or are suspected of having it may be eligible to participate. To join the study, participants will undergo a physical exam and provide information about their medical history. They may also need to provide tissue samples from their tumors, as well as blood, urine, and saliva samples. Additionally, participants might have imaging tests, like MRIs or CT scans, to take pictures of their bodies. Throughout the trial, they may be asked questions about their experience with prostate cancer and could have follow-up visits or phone calls to check in on their health.

Gender

MALE

Eligibility criteria

• * INCLUSION CRITERIA:
• • 1. Adults (greater than or equal to 18 years of age) with biopsy-proven or suspected prostate cancer (elevated PSA abnormal digital rectal exam (DRE) abnormal prostate MRI, or family history) who require and are willing to undergo diagnostic or therapeutic intervention as part of their diagnosis, standard of care treatment, or follow-up/surveillance for their neoplasm.
• • 2. ECOG performance status of 0-2
• • 3. Must be willing and able to provide informed consent
• • 4. PSA \> or equal to 1.0 ng/ml (for patients aged 30 - 49 years) OR
• • 5. PSA \> or equal to 2.5 ng/ml (for patients 50 years or older) OR
• • 6. Abnormal DRE (i.e. enlarged, asymmetric, nodular, firm or tender) OR
• • 7. Abnormal prostate MRI finding OR
• • 8. Family history of first degree relatives (brother or father) with prostate cancer or first-degree relatives (mother or sister) with breast or ovarian cancer
• EXCLUSION CRITERIA:
• • 1. Subjects whose comorbidities would preclude diagnostic or therapeutic intervention.